SolasCure Raises UK£1.2M in Funding


SolasCure, a Cambridge, UK-based biotech startup, raised £1.2m in funding.

Seneca Partners invested:

  • £733k invested via Seneca EIS Portfolio Service, and
  • £500K via Seneca Growth Capital VCT.

The company intends to use the funds for the further development of its wound cleaning product, Aurase®.

Led by Dr. Sam Bakri, Executive Chairman and CEO, SolasCure is developing proprietary technology leveraging biomimicry and evidence-based medicine to empower health care professionals to treat patients with chronic wounds. Its first investigational product, Aurase®, is a hydrogel containing an enzyme cloned from medical maggots that can be used to support healthcare professionals treating patients with chronic wounds.